Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Infect Dis
; 22(12): 1703-1715, 2022 12.
Article
in En
| MEDLINE
| ID: mdl-36113538
Full text:
1
Database:
MEDLINE
Main subject:
Vaccines
/
COVID-19
Type of study:
Clinical_trials
/
Guideline
Limits:
Adolescent
/
Adult
/
Humans
Language:
En
Year:
2022
Type:
Article